China Pharma Unaffected by Beijing Tech Deal Scrutiny: JW CEO
JW Therapeutics CEO: China Pharma Unaffected by Beijing Tech Deal Scrutiny
China's booming pharmaceutical industry is not being impacted by Beijing's tightening scrutiny over deals involving sensitive technologies, according to JW Therapeutics CEO Leo Tian. In an interview with Reuters, Tian stated that cross-border collaborations continue as usual.
Global Drugmakers Eye China
Global drugmakers are increasingly seeking China-developed experimental medicines to cut costs ahead of patent expirations. Analysts predict biotech licensing deals will surge to a fresh record this year.
Meta's Manus Acquisition Blocked
Last month, China ordered U.S. tech giant Meta to unwind its $2 billion-plus acquisition of AI startup Manus, sending a chill across wider industries. However, the pharmaceutical sector remains unaffected.
JW Therapeutics, specializing in cell immunotherapy products, counts Bristol Myers Squibb as its largest shareholder. Tian added that the company is actively seeking partnerships outside China.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
Meta Platforms, Inc.
China's blocking of Meta's acquisition of Manus could negatively impact Meta's growth strategy in China and increases the risk of similar obstacles in other sensitive tech deals.
JW (Cayman) Therapeutics Co. Ltd.
JW Therapeutics CEO stated that cross-border collaborations are unaffected and the company is actively seeking international partnerships, supporting its growth potential and strong position in the industry.
Bristol-Myers Squibb Company
As the largest shareholder of JW Therapeutics, Bristol Myers Squibb may indirectly benefit from JW's positive outlook. However, the news does not directly impact BMY, so the effect is limited.
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…